Literature DB >> 2387698

Botulinum A toxin treatment for eyelid spasm, spasmodic torticollis and apraxia of eyelid opening.

G Defazio1, V Lepore, P Lamberti, P Livrea, E Ferrari.   

Abstract

Botulinum-A toxin (botAtox) was used in the treatment of blepharospasm (BS), idiopathic hemifacial spasm (HFS), idiopathic spasmodic torticollis (ST) and apraxia of eyelid opening (AEO). The injection of 7.5-30 U botAtox per eye spread over 3 or 4 sites in the palpebral part of orbicularis palpebrae (OP) reduced palpebral spasm in 12/13 cases of BS and in 7/8 cases of HFS. The effect lasted for 14.5 weeks on average (range 4-30 weeks). Palpebral ptosis (lasting 1-3 weeks) was the most frequent side effect (16/107 eyes treated) but was not related to dose of botAtox or number of inoculation sites. Injection of 60-160 U botAtox into the sternocleidomastoid, trapezius and splenius capitis muscles reduced ST objectively in 1/4 patients for about 4 weeks. In the other patients the reduction or abolition of the hypertrophy of the previous hyperactive muscles was accompanied by persistence or rearrangement of the dystonia pattern, suggesting a change in the pattern of activity of the neck muscles after botAtox. 5 U botAtox per eye spread over 4 sites in the OP significantly reduced the frequency of the episodes of involuntary eyelid closure in 2 patients with AEO but not BS. The therapeutic effect lasted for 7 months after the first treatment and for 8 months after the second in a 46 year old woman with a 6 month history while the second patient (72 year old parkinsonian) has now completed her 3rd month of treatment.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2387698     DOI: 10.1007/bf02333858

Source DB:  PubMed          Journal:  Ital J Neurol Sci        ISSN: 0392-0461


  20 in total

1.  Botulinum toxin injection therapy for hemifacial spasm.

Authors:  E Tolosa; M J Martí; J Kulisevsky
Journal:  Adv Neurol       Date:  1988

2.  Botulinum toxin for benign essential blepharospasm, hemifacial spasm and age-related lower eyelid entropion.

Authors:  J Carruthers; H A Stubbs
Journal:  Can J Neurol Sci       Date:  1987-02       Impact factor: 2.104

3.  Botulinum toxin in spasmodic torticollis.

Authors:  R Stell; P D Thompson; C D Marsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-07       Impact factor: 10.154

4.  Involuntary closure of eyelids in parkinsonism. Electrophysiological evidence for prolonged inhibition of the levator palpebrae muscles.

Authors:  A Esteban; S Giménez-Roldán
Journal:  J Neurol Sci       Date:  1988-07       Impact factor: 3.181

5.  Botulinum toxin: mechanism of presynaptic blockade.

Authors:  I Kao; D B Drachman; D L Price
Journal:  Science       Date:  1976-09-24       Impact factor: 47.728

Review 6.  Assessment of extrapyramidal disorders.

Authors:  C D Marsden; M Schachter
Journal:  Br J Clin Pharmacol       Date:  1981-02       Impact factor: 4.335

7.  Botulinum toxin injection in the management of lateral rectus paresis.

Authors:  A B Scott; S P Kraft
Journal:  Ophthalmology       Date:  1985-05       Impact factor: 12.079

8.  "Apraxia" of eyelid opening: an involuntary levator inhibition.

Authors:  F E Lepore; R C Duvoisin
Journal:  Neurology       Date:  1985-03       Impact factor: 9.910

9.  Botulinum A toxin injection as a treatment for blepharospasm.

Authors:  A B Scott; R A Kennedy; H A Stubbs
Journal:  Arch Ophthalmol       Date:  1985-03

10.  Controlled trial of botulinum toxin injections in the treatment of spasmodic torticollis.

Authors:  D J Gelb; D H Lowenstein; M J Aminoff
Journal:  Neurology       Date:  1989-01       Impact factor: 9.910

View more
  1 in total

Review 1.  Botulinum toxin in hemifacial spasm: the challenge to assess the effect of treatment.

Authors:  Bettina Wabbels; Peter Roggenkämper
Journal:  J Neural Transm (Vienna)       Date:  2012-01-10       Impact factor: 3.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.